Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

4(66.7%)

N/A

2(33.3%)

6Total

Phase 2(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06343415Not ApplicableCompleted

Robot-assisted Training After Acquired Brain Injury and Disorders of Consciousness

Role: lead

NCT05173896Phase 2Active Not Recruiting

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Role: lead

NCT05355831Not ApplicableRecruiting

Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation

Role: lead

NCT02829502Phase 2Unknown

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

Role: lead

NCT02801032Phase 2Completed

Effect of Tadalafil on Cerebral Large Arteries in Stroke

Role: lead

NCT02838589Phase 2Completed

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

Role: lead

All 6 trials loaded